India Glycols Ltd

Q1 FY27Beverages

India Glycols Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price₹264

Market cap₹2.0K Cr

P/E6.2

Updated18 Sept 2026

Read4 min read

The short version

India Glycols expects a healthy double-digit growth in the potable spirits segment (FY27), driven by deeper penetration in core states and new offerings in deluxe whiskey, rum, and semi-premium vodka segments. India Glycols aims to deliver an EBITDA in excess of INR 500 crores for FY27, with INR 120 crores already achieved in Q1.

From India Glycols Ltd's Q1 FY27 earnings-call transcript · updated 18 Sept 2026.

Revenue & Sales Performance

India Glycols expects a healthy double-digit growth in the potable spirits segment (FY27), driven by deeper penetration in core states and new offerings in deluxe whiskey, rum, and semi-premium vodka segments.
Aim to double volume from FY26 levels with premiumization leading to revenue growth outpacing volume growth.
Project EBITDA for potable spirits to exceed INR 500 crores in FY27 and target INR 1,000 crores within 4-5 years.
The IMFL segment is expected to contribute over 30% of potable spirits revenue.
The Ennature Bio Pharma segment aims for INR 130-150 crores EBITDA in 4-5 years, driven by growth in nicotine business and nutraceutical launches.
Chemicals business to grow steadily with expansion in bio-based specialty chemicals and performance chemicals.
NSU (New Specialties Unit) business aims to grow from INR 150 crores this year to INR 600-700 crores in 4-5 years with modest capex.

Profitability & Margins

India Glycols aims to deliver an EBITDA in excess of INR 500 crores for FY27, with INR 120 crores already achieved in Q1.
Potable Spirits segment targets doubling of volume from last year, driven by deeper market penetration and premium product launches.
The company aspires to achieve EBITDA exceeding INR 1,000 crores in the next 4-5 years, potentially becoming one of the top five alco-bev companies in India.
Ennature Bio Pharma targets an EBITDA of INR 130-150 crores within 4-5 years, supported by new acquisitions, nutraceutical launches, and nicotine business expansion.
Chemicals business expected to grow with innovations and new performance chemicals contributing to margins, aspiring for gross margins near 30% in 5-6 years.
Overall focus on premiumization and geographical expansion, with inorganic growth expected from new brands and states.
Aim to become a debt-free company by FY28, supporting profitable, sustained growth.

See what India Glycols Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

For the NSU (Nutraceuticals and Specialty Units) segment, the planned capex for the current year is modest, approximately INR 5-20 crores, focusing on incremental and modular expansions rather than large-scale investments.
No major large-scale plant investments (INR 400-500 crores) are expected within the next 2 years.
Long-term aspiration includes growing the NSU business to INR 600-700 crores by 2030 with improving profitability.
New technologies and carbon-smart innovations are being explored but are not yet mature for capital allocation.
In renewable materials and performance chemicals, moderate investments are planned, supported by innovation and partnerships.
Acquisition and geographic expansion in the Potable Spirits segment will likely involve some investments, but specific capex figures were not disclosed.

Top-ranked in Beverages

Ranked on what management guided this quarter

5x potential

1Varun Beverages₹1.4L Cr

Rev 2Mar 3

2Fratelli Vineyards Ltd₹565 Cr

Rev 2Mar 3

3₹17.7K Cr

Rev 3Mar 1

4₹12.9K Cr

Rev 3Mar 1

5₹33.2K Cr

Rev 3Mar 3

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

No specific mention of new fundraising through debt or equity in the provided transcript.
Debt levels have reduced during the quarter with finance costs declining from INR45 crores in Q1 FY26 to INR25 crores in Q1 FY27.
The company is targeting becoming a debt-free company from FY28 onwards.
Incremental capex planned for NSU segment is modest (INR5-20 crores) and not expected to require large borrowing.
Business restructuring (de-merger) is progressing with NCLT approval, aiming for clearer focus and potentially attracting investors specific to consumer or B2B businesses.
No explicit statement regarding raising fresh equity or debt funding in the near term.

See what India Glycols Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript of India Glycols Limited's Q1 FY27 Earnings Conference Call does not explicitly provide details on the current or expected order book or pending orders. However, relevant insights include: - Ennature Bio Pharma reported a strong order pipeline, supported by new customer acquisitions and nutraceutical launches. - The nicotine business capacity expansion and sales growth indicate increasing demand. - There is continued focus on strengthening product portfolios and market penetration, which may imply a growing order book. - The joint venture (JV) business is performing well with increasing revenues and profitability. - No specific quantitative details on order book size or pending orders were disclosed in the call. For precise order book or pending order figures, further direct communication with the company is recommended.

India Glycols Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹976 Cr, net profit ₹87 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What India Glycols Ltd's management said in earlier quarters

Others in Beverages this season

BCL Industries Ltd (Q1 FY27)
Supreme Court's allowance for OMCs to procure 1.49 billion liters for Q4 FY25-'26 could add incremental volume (~4.5 crore liters) for the company in next 2-3…
Globus Spirits Ltd (Q1 FY27)
Capacity utilization, especially the UP plant (~25% captive utilization, rest bulk sales with month-to-month optimization). Key concall takeaways from Globus…
Allied Blenders & Distillers Ltd (Q1 FY27)
Prestige & Above segment volumes grew 10.7%, with continued premiumization focus. Key concall takeaways from Allied Blenders's Q1 FY27 earnings call — and how…
Tilaknagar Industries Ltd (Q1 FY27)
PAT grew by 52% in Q1 FY27 but excluding inflation and subsidy impacts, EBITDA margins were closer to 17%. Key concall takeaways from Tilaknagar Inds.'s Q1…

Compare:vs Varun Beverages Ltd vs Radico Khaitan vs United Breweries Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were India Glycols Ltd Q1 FY27 results?

What is India Glycols Ltd share price analysis?

India Glycols Ltd currently shows a neutral. The stock trades at a P/E of 6.2 with a market cap of ₹1,977 Cr. Investors should review the full earnings analysis for detailed insights.

Is India Glycols Ltd planning capital expenditure?

For the NSU (Nutraceuticals and Specialty Units) segment, the planned capex for the current year is modest, approximately INR 5-20 crores, focusing on incremental and modular expansions rather than large-scale investments.

Keep India Glycols Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.